Related Experiment Video
Updated: May 15, 2026
09:50
Application of Chronic Stimulation to Study Contractile Activity-induced Rat Skeletal Muscle Phenotypic Adaptations
Published on: January 25, 2018
Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies
Koichi Okita1, Shintaro Kinugawa, Hiroyuki Tsutsui
1Department of Sport Education, Hokusho University, Ebetsu, Japan. okitak@hokusho-u.ac.jp
Summary
Skeletal muscle abnormalities, not just blood flow issues, cause early fatigue in chronic heart failure (CHF). Understanding these muscle problems is key to developing new treatments for CHF patients.
Area of Science:
- Cardiology
- Exercise Physiology
- Skeletal Muscle Biology
Background:
- Chronic heart failure (CHF) is clinically defined by exercise intolerance and early muscular fatigue.
- Historically, CHF-related exercise limitation was attributed solely to impaired blood flow to muscles, leading to premature acidosis.
- However, interventions improving cardiac output did not consistently enhance exercise capacity in CHF patients.
Purpose of the Study:
- To review the clinical significance of intrinsic skeletal muscle abnormalities in chronic heart failure.
- To explore how these abnormalities contribute to exercise intolerance in CHF.
- To highlight the potential for novel therapeutic strategies targeting skeletal muscle dysfunction.
Main Methods:
- Literature review of studies investigating skeletal muscle function in chronic heart failure.
- Analysis of evidence linking intrinsic muscle changes to exercise intolerance.
- Synthesis of findings regarding the role of anaerobic metabolism in CHF pathophysiology.
Main Results:
- Evidence indicates that intrinsic skeletal muscle abnormalities are present in patients with CHF.
- These muscle abnormalities contribute to early onset of anaerobic metabolism during exercise.
- Abnormalities in skeletal muscle are a significant factor limiting exercise tolerance in CHF.
Conclusions:
- Skeletal muscle abnormalities play a crucial role in the exercise intolerance seen in chronic heart failure.
- Understanding these peripheral muscle issues is vital for improving current therapies like exercise training and pharmacological treatments.
- Targeting skeletal muscle dysfunction may offer a promising avenue for developing novel therapies to enhance CHF prognosis.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...